Launch of the Post-ROSC ECG Analysis using AI (PEACE AI) Validation Study
We are excited to announce the latest multi-center validation study of our AI platform, PMcardio. This study evaluates the effectiveness of our AI model (Queen of Hearts) in detecting Occlusive Myocardial Infarction (OMI) using 12-lead ECGs recorded in patients who have been resuscitated after an out-of-hospital cardiac arrest (OHCA).
Advancing the Cardiac Chain of Survival: Detection of Occlusive Myocardial Infarction in Out-Of-Hospital Cardiac Arrest (OHCA) Patients
At Powerful Medical, we are at the forefront of innovation, and we are excited to announce the latest multi-center validation study of our AI platform, PMcardio. This study evaluates the effectiveness of our AI model (Queen of Hearts) in detecting Occlusive Myocardial Infarction (OMI) using 12-lead ECGs recorded in patients who have been resuscitated after an out-of-hospital cardiac arrest (OHCA).
Background
Diagnosing OMI after a resuscitated OHCA remains a significant challenge in emergency and cardiology settings. Although ST-Elevation Myocardial Infarction (STEMI) millimeter criteria are commonly used, acute thrombotic occlusive lesions can exist even without typical ST-elevation, making detection of STEMI difficult. This study addresses that gap by utilizing our advanced AI model to detect OMI based on 12-lead ECGs recorded immediately post-Return of Spontaneous Circulation (ROSC).
The Need for Advanced Detection in Post-ROSC OMI Patients
The 2023 ESC guidelines for Acute Coronary Syndromes introduced new complexities in the management of OHCA patients, particularly with the recommendation against routine immediate coronary angiography (CAG) for hemodynamically stable patients without persistent ST-segment elevation or its equivalents (Class IIIA).
This change presents a challenge, as the definition of STEMI equivalents remains ambiguous, potentially leading to missed diagnoses at the critical early stages. Despite this shift, many centers continue to take a proactive approach, performing immediate CAG in OHCA cases. There remains a significant clinical need to identify patients without obvious ST-elevation who may still have an occluded artery, particularly in facilities without PCI capabilities.
Study Overview
Led by Dr. Simone Savastano at Fondazione IRCCS Policlinico San Matteo in Pavia, Italy, this study will involve key collaborators – Dr. Thomas Keeble and Dr. Uzma Sajjad at the Essex Cardiothoracic Centre, UK and Dr. Sascha Macherey and Dr. Christoph Adler at University Hospital Cologne, Germany. The analysis will include over 1,000 post-ROSC ECGs, with PMcardio’s AI predictions compared against invasive coronary angiographic findings.
Upcoming Presentations
The preliminary results of this groundbreaking study will be shared at the European Resuscitation Council Congress (Resuscitation 2024) and other leading cardiology and emergency medicine conferences throughout the year. Stay tuned for more detailed results following the conference presentations.
Stay Informed
We are excited to share the full details of this groundbreaking study with the medical community and beyond. Keep an eye on our website for further updates and insights as we continue to refine our AI models and push the boundaries of cardiovascular care.
Share this article
About PMcardio
PMcardio is a CE-marked Class IIb AI medical device that interprets any 12-lead ECG — from a photo or a digital file — in seconds. It detects 50+ ECG findings, including occlusion myocardial infarction (OMI) — the acute coronary occlusions that conventional STEMI criteria miss in over half of cases. Its Queen of Hearts™ OMI model holds FDA Breakthrough Device Designation, and PMcardio is already used by 100,000+ clinicians who have analyzed more than 2.5 million ECGs.
About Powerful Medical
Powerful Medical is a medical-technology company using artificial intelligence to transform how cardiovascular disease — the world’s leading cause of death — is diagnosed. Founded in 2017, it built PMcardio, the world’s first AI medical device to detect acute coronary occlusion (OMI) from an ECG. Its research is published in the European Heart Journal – Digital Health and validated across 25+ clinical studies, and its Queen of Hearts™ model earned FDA Breakthrough Device Designation. To date, PMcardio has supported the detection of 120,000+ heart attacks across 150+ hospital deployments worldwide.
